| Literature DB >> 33462684 |
Valeria Merico1, Jacopo Francesco Imberti2, Mario Zanoni1, Giuseppe Boriani2, Silvia Garagna1,3, Roberto Imberti4.
Abstract
Mutations in lysyl oxidase (LOX) genes cause severe vascular anomalies in mice and humans. LOX activity can be irreversibly inhibited by the administration of β-aminoproprionitrile (BAPN). We investigated the mechanisms underlying the damage to the ascending thoracic aorta induced by LOX deficiency and evaluated whether 6-propylthiouracil (PTU) can afford protection in rats. BAPN administration caused disruption of the ascending aortic wall, increased the number of apoptotic cells, stimulated TGF-β signaling (increase of nuclear p-SMAD2 staining), and up-regulated the expression of metalloproteinases-2 and -9. In BAPN-treated animals, PTU reduced apoptosis, p-SMAD2 staining, MMP-2, and -9 expression, and markedly decreased the damage to the aortic wall. Our results suggest that, as in some heritable vascular diseases, enhanced TGF-β signaling and upregulation of MMP-2 and -9 can contribute to the pathogenesis of ascending aorta damage caused by LOX deficiency. We have also shown that PTU, a drug already in clinical use, protects against the effects of LOX inhibition. MMP-2 and -9 might be potential targets of new therapeutic strategies for the treatment of vascular diseases caused by LOX deficiency.Entities:
Keywords: Ascending aorta disruption; BAPN; Lysyl oxidase; Metalloproteinase-2 and -9; Propylthiouracil; TGF-β signaling
Year: 2021 PMID: 33462684 DOI: 10.1007/s00380-020-01750-6
Source DB: PubMed Journal: Heart Vessels ISSN: 0910-8327 Impact factor: 2.037